Cannabinoids for Scleroderma
Project CBD
OCTOBER 10, 2019
Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2. Referred to as a “selective CB2 agonist ,” such a compound would appear to have potential as a treatment for scleroderma.
Let's personalize your content